An overview of cancer/testis antigens expression in classical Hodgkin's lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients by Inaoka, Riguel Jun et al.
RESEARCH ARTICLE Open Access
An overview of cancer/testis antigens expression
in classical Hodgkin’s lymphoma (cHL) identifies
MAGE-A family and MAGE-C1 as the most
frequently expressed antigens in a set of Brazilian
cHL patients
Riguel J Inaoka1†, Achim A Jungbluth2†, Otávio CG Baiocchi1, Mariane CG Assis1, Nicole C Hanson2,
Denise Frosina2, Jodie Tassello2, Adriana B Bortoluzzo3, Antonio C Alves4 and Gisele WB Colleoni1*
Abstract
Background: Cancer/testis antigens are considered potential targets for immunotherapy due to their tumor-
associated expression pattern. Although recent studies have demonstrated high expression of CT45 in classical
Hodgkin’s lymphomas (cHL), less is known about the expression pattern of other families of CTAs in cHL. We aim
to evaluate the expression of MAGE-A family, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO1 and GAGE family in cHL and
to correlate their expression with clinical and prognostic factors in cHL.
Methods: Tissue microarray was generated from 38 cHL archival cases from Pathology Department of Universidade
Federal de Sao Paulo. Immunohistochemistry (IHC) was done using the following panel of antibodies: MAGE-A family
(MA454, M3H67, 57B and 6C1), GAGE (#26), NY-ESO-1 (E978), MAGE-C1/CT7 (CT7-33) and MAGE-C2/CT10 (CT10#5).
Results: We found CTA expression in 21.1% of our cHL series. Among the tested CTAs, only MAGE-A family 7/38
(18.4%) and MAGE-C1/CT7 5/38 (13.2%) were positive in our cHL samples. We found higher CTA positivity in
advanced stage (28.6%) compared to early stage (11.8%) disease, but this difference was not statistically significant.
Analysis of other clinicopathological subgroups of cHL including histological subtypes, EBV status and response to
treatment also did not demonstrate statistical significant differences in CTA expression.
Conclusion: We found CTA expression in 21.1% of cHL samples using our panel. Our preliminary findings suggest
that from all CTAs included in this study, MAGE-A family and MAGE-C1/CT7 are the most interesting ones to be
explored in further studies.
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Background
Classical Hodgkin lymphoma (cHL) is characterized by
the presence of rare neoplastic Hodgkin-Reed-Sternberg
(HRS) cells embedded in an inflammatory background
of nonmalignant cells [1,2]. The mechanisms of how
HRS cells survive in this inflammatory milieu remain
controversial and the identification of specific antigens
restricted to the HRS cells is crucial for the develop-
ment of new treatment strategies, augmenting host anti-
tumor immunological response.
Cancer/testis antigens (CTAs) are considered potential
candidates for antigen-specific cancer immunotherapy
due to their particular characteristics of high immuno-
genicity with no or highly restricted expression in nor-
mal tissues (testis and placenta) [3]. There are more
than 100 CTA genes reported in the literature to date
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[4] but biological function of most CTAs remains poorly
understood. Recent studies have provided some evi-
dence that CTAs may have antiapoptotic properties
rather than regulating cell proliferation or adhesion in
cancer [5-12] and it could explain the persistence of
minimal residual disease in some malignancies, even in
cHL, where the potential of cure is very high. The fre-
quency of CTA expression is highly variable among dif-
ferent tumor types. Melanoma, ovarian cancer, and lung
cancer are considered tumors with high frequency of
CTA expression, while hematopoietic malignancies,
renal, colon and pancreatic cancers, are considered
tumors with low frequency of CTA expression [3].
Some exceptions to this observation among hemato-
poietic malignancies are the high expression of CT7/
MAGE-C1 in multiple myeloma [13,14], and CT45 in
classical Hodgkin lymphoma (cHL) [15,16]. Studies cor-
relating CTA expression with clinicopathological fea-
tures in different tumor types have demonstrated the
association of CTA positivity with higher tumor grade,
advanced stage or metastatic disease and worse clinical
outcome [13,17-25].
Considering that the available information about CTA
expression in cHL is scarce and heterogeneous regard-
ing methods and samples, we investigated the immuno-
histochemical expression against a broad panel of CTAs
in cHL tissue samples to evaluate their potential as
prognostic markers and candidates for immunothera-
peutic approach in cHL patients.
Methods
We retrospectively reviewed all cases of cHL diagnosed
between 2004 and 2008 at the University Hospital São
Paulo. Medical records from 38 adult patients (> 18
years) with cHL were reviewed and information on sex,
age at diagnosis, Ann Arbor clinical stage, laboratory
results, treatment used and response were retrieved. The
response to primary treatment was classified according
to the International Workshop criteria [26]. Patients
treated with radiotherapy alone as first-line therapy and
with positive HIV serology were excluded from this
study. For this study, only cHL patients with tumors
whose histology could be confirmed by hemopathologist
re-review and paraffin blocks with enough material for
tissue microarray (TMA) construction could be retrieved
were studied. Sufficient data was obtained from 38
patients. All patients received ABVD (doxorubicin, bleo-
mycin, vinblastine and dacarbazine) chemotherapy pro-
tocol and had locally extensive or advanced stage
disease at diagnosis. Locally extensive disease was
defined by clinical stages I-II-A/B (Ann Arbor Staging
System) with massive mediastinal adenopathy (mass >
1/3 maximum intrathoracic diameter on standing pos-
tero-anterior chest x-rays), and advanced disease defined
as stages III-IV. Determination of EBV-association in
tumor biopsies was done by immunohistochemistry for
latent membrane protein 1 (LMP1) following previously
established procedures [27]. Samples from a known
EBV-related cHL served as a positive control in each
run.
This research was approved by the Ethical Review
Committee of our Institution according to the Declara-
tion of Helsinki (0998/07), and all patients provided
written informed consent.
Formalin-fixed paraffin embedded tissues of 38 cHL
were obtained from the archives of the Department of
Pathology, Hospital São Paulo, UNIFESP, Brazil. All HL
cases were classified according to WHO classification
for hematologic malignancies [28] as cHL. 25 (65.8%)
cases were classified as nodular sclerosis subtype, 9
(23.7%) as mixed cellularity, 2 (5.3%) as lymphocyte pre-
dominant and 2 (5.3%) were unclassified. Table 1 sum-
marizes the clinical data of these patients. Slides from
all cases were reviewed and representative blocks were
chosen for tissue microarray.
Two core-needle biopsies (1.0 mm diameter) from
tumor representative areas of each HL case were
obtained and then re-embedded in an array master
block using techniques originally developed by Kononen
et al. [29] and then modified by Hedvat et al. [30] and
Beecher Instruments (Sun Prairie, WI, USA) arraying
device.
The mAbs used for immunohistochemistry are listed
in Table 2 [22,31-38]. The evaluation of MAGE-A
family expression was done using a “MAGE-A cocktail”
Table 1 Clinical data of Hodgkin’s lymphoma patients (n
= 38).
Clinical data n %
Median age: 28.5 (16-57)
Gender
Male 18 47.4
Female 20 52.6
HL Subtype
Nodular sclerosis 25 65.8
Mixed cellularity 9 23.7
Lymphocyte predominant 2 5.3
Unclassified 2 5.3
Ann Arbor staging
Early (I or II) 17 44.7
Advanced (III or IV) 21 55.3
EBV status
Negative 21 55.3
Positive 17 44.7
Response
Complete response 30 78.9
Relapsed/refractory 8 21.1
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containing the following antibodies: MA454, M3H67, 57B
and 6C1, that allowed an overview of MAGE-A family
(MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-
A6 MAGE-A10 and MAGE-A12) expression in HL.
Testis with preserved spermatogenesis was used as
positive controls and reactive lymph nodes and tonsils
samples were used as negative controls for all
antibodies.
Associations between the variables were tested by the
Pearson Chi-Square Test (X2). Mann-Whitney test was
used to perform mean comparisons. A p value lower
than 0.05 was considered as statistically significant.
Results
The majority of patients presented advanced disease and
B symptoms at diagnosis. We found a strong correlation
between anti-LMP1 identification on HRS cells and
response to ABVD regimen, with all 21 EBV-negative
patients achieving complete response (CR) and only 9/
17 (52.9%) of EBV-positive patients achieving CR (p <
0.001). None of other clinical subgroups presented sta-
tistical significant difference in treatment response, as
demonstrated on Table 3.
Due to the low overall CTA expression in cHL TMA,
positivity was not graduated, and the samples were ana-
lyzed as positive (any degree of positivity) or negative.
Figure 1 demonstrates three nodular sclerosis cHL sam-
ples stained for CT7. Sample (A) shows diffuse positiv-
ity, sample (B) is focally positive and sample (C) is a
negative case.
Eight (21.1%) of 38 cHL cases expressed at least one
CTA, being 6/25 nodular sclerosis and 2/9 mixed cellu-
larity. Among the 8 positive cases, 6/20 were female and
2/18 male. Despite the difference found in CTA expres-
sion between early (11.8%) and advanced stage (28.6%)
disease, this difference was not statistically significant (p
= 0.195). None of the other clinical subgroups of cHL
according to histological subtypes, EBV status and
response to treatment also presented statistically signifi-
cant difference in CTA expression, as demonstrated on
Table 4. Among the tested CTAs, only MAGE-A family
7/38 (18.4%) and MAGE-C1/CT7 5/38 (13.2%) were
positive in our cHL samples. CT10/MAGE-C2, GAGE
and NY-ESO-1 were negative in all samples. Four of
these samples were positive for both CTAs.
Discussion and conclusions
In our study, the majority of cases had B symptoms
(68.4%) and advanced disease (65.7%) at diagnosis, as
Table 2 Monoclonal antibodies used in immunohistochemical analyses.
Monoclonal
antibody
Mainly recognized
Antigen(s)
Source Cellular staining
pattern
References
MA454* MAGE-A1 LICR Cytoplasmic [22,31-34]
M3H67* MAGE-A3 LICR Nuclear & cytoplasmic [22,33,34]
57B * MAGE-A4 Dr Spagnoli, Basel, Switzerland Nuclear & cytoplasmic [22,33,34]
6C1* MAGE-A 1, 2, 3, 4, 6, 10 and 12 LICR Nuclear & cytoplasmic [35]
CT7-33 CT7/MAGE-C1 LICR Nuclear & cytoplasmic [22,33,34]
CT10#5 CT10/MAGE-C2 LICR Nuclear [35-37]
#26 GAGE BD Bioscience Nuclear & cytoplasmic [35,36]
E978 NY-ESO-1 LICR Cytoplasmic [36,38]
*MAbs included in “MAGE-A cocktail” used to search MAGE-A family expression in HL TMA.
Table 3 Hodgkin’s lymphoma treatment response
analysis.
Clinical data N Complete
response
(%)
N Refractory/
relapsed
(%)
p
value
Gender
Male 13 72.2 5 27.8 0.286
Female 17 85.0 3 15.0
HL Subtype
Nodular sclerosis 21 84.0 4 16.0 0.220
Mixed cellularity 5 55.6 4 44.4
Lymphocyte
predominant
2 100.0 0 0
Unclassified 2 100.0 0 0
Ann Arbor staging
Early (I or II) 15 88.2 2 11.8 0.195
Advanced (III or IV) 15 71.4 6 28.6
EBV status
Negative 21 100.0 0 0 <
0.001
Positive 9 52.9 8 47.1
CTA positivity
0 CT 24 80.0 6 20.0 0.954
> or = 1 6 75.0 2 25.0
MAGE-A
negative 24 77.4 7 22.6 0.538
positive 6 85.7 1 14.3
CT7
negative 27 81.8 6 18.2 0.279
positive 3 60 2 40
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seen in other developing countries. The positivity for
EBV was 44.7% in our cohort of cHL. According to lit-
erature, the incidence of EBV-related cHL is highly vari-
able among different populations and higher EBV
positivity has seen in underdevelopment countries com-
pared to developed ones. In previous studies, Oliveira et
al. and Vassallo et al. found EBV positivity in 52.5% and
64.1% of Brazilian cHL patients respectively [39,40]. The
prognostic significance of EBV expression is controver-
sial, but the correlation of EBV positivity and poorer
outcome has been described in some studies [41]. The
difference of treatment failure rate between EBV positive
(47.1%) and EBV negative patients (0%) was statistically
significant (p < 0.001) in our cohort.
Using our panel, we found expression of CTAs in
21.1% of cHL patients. MAGE-A family was positive in
18.4% and MAGE-C1/CT7 in 13.2% of samples. Despite
the availability of few studies evaluating the expression of
CTAs in cHL to date, our findings are in agreement with
most of studies that evaluated the expression of same
CTAs in cHL using RT-PCR or immunohistochemical
analysis. Expression of MAGE-A family in cHL was eval-
uated by Chambost et al. [42] and it was positive in 28%
of cHL samples using RT-PCR and in 21% cHL tissue
sections using immunohistochemistry with an anti-
MAGE-A4 antibody. Recently, Chen et al. [15] described
the expression of CT45 in cHL and other B-cell lympho-
mas. They found expression of CT45 in 58% of cHL by
immunohistochemistry. A previous study published by
Heidebrecht et al. [16] also described the expression of
CT45 in 55% of pediatric and adolescent cHL using
immunohistochemistry, reinforcing CT45 as one of the
most promising CTA to be explored in cancer vaccine
trials for cHL to date. Unfortunately, CT45 could not be
included in our immunohistochemistry panel because
specific antibodies were not commercially available,
neither at Ludwig Institute for Cancer Research - NY,
our collaborating center at the time of this study.
Another CTA family whose expression pattern was stu-
died in cHL was SSX. Colleoni et al. [43] found positivity
of SSX family in 15.6% of 32 cHL samples. In summary,
except for CT45, the available studies suggest an overall
positivity for other CTA families tested in cHL of about
10% to 30%. We found a tendency to a higher CTA
expression among advanced stage disease compared to
early stage disease in our cHL samples as described in lit-
erature [13,17-25], but the difference did not reach statis-
tical significance.
Therefore, our results emphasize the importance of
studying CTAs expression in a Brazilian set of patients.
We acknowledge the fact that our small sample size
may have influenced these results, and larger studies
are warranted. However, our results point toward a
relationship between CTA expression and disease
severity.
Further studies investigating CTA expression on HRS
cells and how they can elicit humoral and cytotoxic
response will contribute not only to our understanding
on the pathogenesis of cHL but also to the development
Figure 1 Immunohistochemical staining of three different nodular sclerosis cHL samples using an anti-CT7 antibody (CT7-33). (A)
Diffuse positivity. (B) Focal positivity. (C) Negative staining for CT7-33; ×400.
Table 4 Hodgkin’s lymphoma CTA expression analysis.
Clinical data N 0 CTA
(%)
N > or = 1 CTA
(%)
p
value
HL Subtype
Nodular sclerosis 19 76.0 6 24.0 0.752
Mixed cellularity 7 77.8 2 22.2
Lymphocyte predominant 2 100.0 0 0
Unclassified 2 100.0 0 0
Ann Arbor staging
Early (I or II) 15 88.2 2 11.8 0.195
Advanced (III or IV) 15 71.4 6 28.6
EBV status
Negative 17 81.0 4 19.0 0.522
Positive 13 76.5 4 23.5
Treatment Response
Complete response 24 80.0 6 20.0 0.954
Non Complete response 6 75.0 2 25.0
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of new CTA-directed immunotherapy, particularly for
advanced stage cases and for patients who did not
achieve a complete response after initial therapy.
Acknowledgements
This work was partially supported by grants from CAPES (RJI) and CNPq
(GWBC).
Author details
1Departamento de Oncologia Clinica e Experimental, Universidade Federal
de Sao Paulo. Rua Botucatu, 740, Vila Clementino, Sao Paulo, SP 04023-900,
Brazil. 2Ludwig Institute for Cancer Research New York Branch, Memorial
Sloan-Kettering Cancer Center, 1275 York Avenue, Box 32, New York, NY
10021-6007, USA. 3Instituto de Ensino e Pesquisa, Insper. Rua Quata, 300, Vila
Olimpia, Sao Paulo, SP 04546-042, Brazil. 4Departamento de Anatomia
Patologica, Universidade Federal de Sao Paulo. Rua Botucatu, 740, Vila
Clementino, Sao Paulo, SP 04023-900, Brazil.
Authors’ contributions
This manuscript is a product of a PhD research project (RJI) conducted
under the supervision of GWBC. AAJ, NH, DF and JT (Ludwig Institute for
Cancer Research - NY) participated in the decision of CTAs to be included in
our study, provided the anti-CTA antibodies and carried out the
immunohistochemistry. OCGB and MCGA participated in acquisition, analysis
and interpretation of cHL clinical data. ABB performed the statistical analysis.
ACA reviewed all cHL tumor sample slides. RJI participated in all steps
described above and drafted the manuscript. GWBC have been involved in
conception and design of this study, analysis, interpretation of data and final
approval of the version to be published. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 27 May 2011 Accepted: 28 September 2011
Published: 28 September 2011
References
1. Skinnider BF, Mak TW: The role of cytokines in classical Hodgkin
lymphoma. Blood 2002, 99:4283-4297.
2. Poppema S: Immunobiology and pathophysiology of Hodgkin
lymphomas. Hematology Am Soc Hematol Educ Program 2005, 231-238.
3. Caballero OL, Chen YT: Cancer/testis (CT) antigens: potential targets for
immunotherapy. Cancer Sci 2009, 100(11):2014-21.
4. Almeida LG, Sakabe NJ, de Oliveira AR, Silva MC, Mundstein AS, Cohen T,
Chen YT, Chua R, Gurung S, Gnjatic S, Jungbluth AA, Caballero OL,
Bairoch A, Kiesler E, White SL, Simpson AJ, Old LJ, Camargo AA,
Vasconcelos AT: CTdatabase: a knowledge-base of high-throughput and
curated data on cancer-testis antigens. Nucleic Acids Res 2009, 37:D816-9.
5. Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S,
Kobold S, Bartels K, Pabst C, Lajmi N, Gordic M, Stahl T, Zander AR,
Bokemeyer C, Kröger N: Cancer-testis antigens MAGE-C1/CT7 and MAGE-
A3 promote the survival of multiple myeloma cells. Haematologica 2010,
95(5):785-93.
6. Zhu X, Asa SL, Ezzat S: Fibroblast growth factor 2 and estrogen control
the balance of histone 3 modifications targeting MAGE-A3 in pituitary
neoplasia. Clin Cancer Res 2008, 14:1984-96.
7. Yang B, O’Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, Gravekamp C,
Setaluri V, Peters N, Hoffmann FM, Peng H, Ivanov AV, Simpson AJ,
Longley BJ: MAGE-A, mMage-b, and MAGE-C proteins form complexes
with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell
lines. Cancer Res 2007, 67:9954-62.
8. Peikert T, Specks U, Farver C, Erzurum SC, Comhair SA: Melanoma antigen
A4 is expressed in non-small cell lung cancers and promotes apoptosis.
Cancer Res 2006, 66:4693-700.
9. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA,
Rodolfo M, Schneider C: MAGE-A tumor antigens target p53
transactivation function through histone deacetylase recruitment and
confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA
2006, 103:11160-5.
10. Bai S, He B, Wilson EM: Melanoma antigen gene protein MAGE-11
regulates androgen receptor function by modulating the interdomain
interaction. Mol Cell Biol 2005, 25:1238-57.
11. Nagao T, Higashitsuji H, Nonoguchi K, Sakurai T, Dawson S, Mayer RJ, Itoh K,
Fujita J: MAGE-A4 interacts with the liver oncoprotein gankyrin and
suppresses its tumorigenic activity. J Biol Chem 2003, 278:10668-74.
12. Cilensek ZM, Yehiely F, Kular RK, Deiss LP: A member of the GAGE family
of tumor antigens is an anti-apoptotic gene that confers resistance to
Fas/CD95/APO-1, Interferon-gamma, taxol and gamma-irradiation. Cancer
Biol Ther 2002, 1:380-7.
13. Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS,
Chauffaille ML, Andriolo A, Caballero OL, Zago MA, Colleoni GW: Prognostic
impact of cancer/testis antigen expression in advanced stage multiple
myeloma patients. Cancer Immun 2008, 8:2.
14. Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D,
Chen YT, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ: The cancer-testis
antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in
multiple myeloma and correlate with plasma-cell proliferation. Blood
2005, 106:167-74.
15. Chen YT, Chadburn A, Lee P, Hsu M, Ritter E, Chiu A, Gnjatic S,
Pfreundschuh M, Knowles DM, Old LJ: Expression of cancer testis antigen
CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proc
Natl Acad Sci USA 2010, 107(7):3093-8.
16. Heidebrecht HJ, Claviez A, Kruse ML, Pollmann M, Buck F, Harder S,
Tiemann M, Dörffel W, Parwaresch R: Characterization and expression of
CT45 in Hodgkin’s lymphoma. Clin Cancer Res 2006, 12:4804-11.
17. Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, O’Neill D,
Zavilevich K, Albukh T, Christos P, Mazumdar M, Pavlick A, Polsky D,
Shapiro R, Berman R, Spira J, Busam K, Osman I, Bhardwaj N: Expression of
the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant
melanoma (MM) - correlation with prognostic factors. Cancer Immun
2007, 7:11.
18. Goydos JS, Patel M, Shih W: NY-ESO-1 and CTp11 expression may
correlate with stage of progression in melanoma. J Surg Res 2001,
98:76-80.
19. Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL, Luo J,
Getzenberg RH, Kulkarni P: Expression of cancer/testis antigens in
prostate cancer is associated with disease progression. Prostate 2010,
70(16):1778-87.
20. Riener MO, Wild PJ, Soll C, Knuth A, Jin B, Jungbluth A, Hellerbrand C,
Clavien PA, Moch H, Jochum W: Frequent expression of the novel cancer
testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer
2009, 124:352-7.
21. Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C,
Stahl T, Cao Y, Zander AR, Bokemeyer C, Kröger N: Longitudinal analysis
and prognostic effect of cancer-testis antigen expression in multiple
myeloma. Clin Cancer Res 2009, 15:1343-52.
22. Perez D, Herrmann T, Jungbluth AA, Samartzis P, Spagnoli G, Demartines N,
Clavien PA, Marino S, Seifert B, Jaeger D: Cancer testis antigen expression
in gastrointestinal stromal tumors: new markers for early recurrence. Int
J Cancer 2008, 123(7):1551-5.
23. Bellati F, Napoletano C, Tarquini E, Palaia I, Landi R, Manci N, Spagnoli G,
Rughetti A, Panici PB, Nuti M: Cancer testis antigen expression in primary
and recurrent vulvar cancer: association with prognostic factors. Eur J
Cancer 2007, 43(17):2621-7.
24. Kim J, Reber HA, Hines OJ, Kazanjian KK, Tran A, Ye X, Amersi FF,
Martinez SR, Dry SM, Bilchik AJ, Hoon DS: The clinical significance of
MAGEA3 expression in pancreatic cancer. Int J Cancer 2006, 118:2269-75.
25. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC, Resnick MB:
Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in
serous ovarian neoplasms. Clin Cancer Res 2003, 9:6453-60.
26. Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P,
Thomas J, Uyttebroeck A, Mortelmans L, De Wolf-Peeters C, Verhoef G:
Hodgkin lymphoma: Response assessment by revised International
Workshop Criteria. Leuk Lymphoma 2007, 48:1539-1547.
27. Campos AH, Aldred VL, Ribeiro KC, Vassallo J, Soares FA: Role of
immunoexpression of nitric oxide synthases by Hodgkin and Reed-
Sternberg cells on apoptosis deregulation and on clinical outcome of
classical Hodgkin lymphoma. Mol Cell Biochem 2009, 321:95-102.
Inaoka et al. BMC Cancer 2011, 11:416
http://www.biomedcentral.com/1471-2407/11/416
Page 5 of 6
28. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J,
Vardiman JW: World Health Organization Classification of Tumours.
Pathology and Genetics of Tumours of Haematopoietic and Lymphoid
Tissues. IARC Press, Lyon 2008.
29. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S,
Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for
high-throughput molecular profiling of tumor specimens. Nat Med 1998,
4:844-847.
30. Hedvat CV, Hegde A, Chaganti RS, Chen B, Qin J, Filippa DA, Nimer SD,
Teruya-Feldstein J: Application of tissue microarray technology to the
study of non-Hodgkin’s and Hodgkin’s lymphoma. Hum Pathol 2002,
33:968-974.
31. Chen YT, Stockert E, Chen Y, Garin-Chesa P, Rettig WJ, van der Bruggen P,
Boon T, Old LJ: Identification of the MAGE-1 gene product by
monoclonal and polyclonal antibodies. Proc Natl Acad Sci USA 1994,
91(3):1004-8.
32. Jungbluth AA, Stockert E, Chen YT, Kolb D, Iversen K, Coplan K,
Williamson B, Altorki N, Busam KJ, Old LJ: Monoclonal antibody MA454
reveals a heterogeneous expression pattern of MAGE-1 antigen in
formalin-fixed paraffin embedded lung tumours. Br J Cancer 2000,
83(4):493-7.
33. Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K,
Kolb D, Geller MD, Hassoun H, Kewalramani T, Comenzo RL, Coplan K,
Chen YT, Jungbluth AA: Expression of cancer/testis (CT) antigens MAGE-
A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant
gammopathies is heterogeneous and correlates with site, stage and risk
status of disease. Cancer Immun 2003, 3:9.
34. Nelson PT, Zhang PJ, Spagnoli GC, Tomaszewski JE, Pasha TL, Frosina D,
Caballero OL, Simpson AJ, Old LJ, Jungbluth AA: Cancer/testis (CT)
antigens are expressed in fetal ovary. Cancer Immun 2007, 7:1.
35. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA:
Cancer-testis antigens: expression and correlation with survival in
human urothelial carcinoma. Clin Cancer Res 2006, 12(18):5442-7.
36. Oba-Shinjo SM, Caballero OL, Jungbluth AA, Rosemberg S, Old LJ,
Simpson AJ, Marie SK: Cancer-testis (CT) antigen expression in
medulloblastoma. Cancer Immun 2008, 8:7.
37. Zhuang R, Zhu Y, Fang L, Liu XS, Tian Y, Chen LH, Ouyang WM, Xu XG,
Jian JL, Güre AO, Fortunato S, Ritter G, Old LJ, Simpson AJ, Chen YT, Jin B,
Jungbluth AA: Generation of monoclonal antibodies to cancer/testis (CT)
antigen CT10/MAGE-C2. Cancer Immun 2006, 6:7.
38. Vaughan HA, Svobodova S, Macgregor D, Sturrock S, Jungbluth AA,
Browning J, Davis ID, Parente P, Chen YT, Stockert E, St Clair F, Old LJ,
Cebon J: Immunohistochemical and molecular analysis of human
melanomas for expression of the human cancer-testis antigens NY-ESO-
1 and LAGE-1. Clin Cancer Res 2004, 10(24):8396-404.
39. Souza EM, Baiocchi OC, Zanichelli MA, Alves AC, Assis MG, Eiras DP,
Dobo C, Oliveira JS: Impact of Epstein-Barr virus in the clinical evolution
of patients with classical Hodgkin’s lymphoma in Brazil. Hematol Oncol
2010, 28(3):137-41.
40. Vassallo J, Metze K, Traina F, de Souza CA, Lorand-Metze I: Expression of
Epstein-Barr virus in classical Hodgkin’s lymphomas in Brazilian adult
patients. Haematologica 2001, 86(11):1227-8.
41. Diepstra A, van Imhoff GW, Schaapveld M, Karim-Kos H, van den Berg A,
Vellenga E, Poppema S: Latent Epstein-Barr virus infection of tumor cells
in classical Hodgkin’s lymphoma predicts adverse outcome in older
adult patients. J Clin Oncol 2009, 27(23):3815-21.
42. Chambost H, Van Baren N, Brasseur F, Godelaine D, Xerri L, Landi SJ,
Theate I, Plumas J, Spagnoli GC, Michel G, Coulie PG, Olive D: Expression of
gene MAGE-A4 in Reed-Sternberg cells. Blood 2000, 95(11):3530-3.
43. Colleoni GW, Capodieci P, Tickoo S, Cossman J, Filippa DA, Ladanyi M:
Expression of SSX genes in the neoplastic cells of Hodgkin’s lymphoma.
Hum Pathol 2002, 33(5):496-502.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/416/prepub
doi:10.1186/1471-2407-11-416
Cite this article as: Inaoka et al.: An overview of cancer/testis antigens
expression in classical Hodgkin’s lymphoma (cHL) identifies MAGE-A
family and MAGE-C1 as the most frequently expressed antigens in a set
of Brazilian cHL patients. BMC Cancer 2011 11:416.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Inaoka et al. BMC Cancer 2011, 11:416
http://www.biomedcentral.com/1471-2407/11/416
Page 6 of 6
